Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The 1-year survival rate for lung cancer has increased from 37% in 1975 to 42% in 1999-2001, largely because of improvements to surgical techniques and with combined therapies.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • Cancer Survival Rate Increasing